Middle Market Financing and Investing


Business Overview

Solar Capital Partners has a dedicated team of life science investment professionals who specialize in providing highly structured senior secured loans to private or publicly-traded small-cap drug and medical device companies with substantial equity invested to date - typically later stage drug or product development companies that are approaching, or are in transition to commercialization. We focus on companies that are backed by top-tier VC backers, have experienced management teams and strong board of directors.

SCP launched the Solar Life Science Lending (LSL) platform in Q1 2014 with the hiring of the founder and CIO of G.E. Capital’s life science lending business. With the addition a year later of the core investment team from G.E. that had worked with the founder, our life science investment team is comprised of a core group of experienced professionals who have worked together for 17+ years.

Since inception, the principals have invested approximately $3.2 billion in life science and medical device later stage development companies, including originating over $940 million in over 65 transactions since joining the SCP platform. We leverage the teams’ deep relationships with VC’s, CEO’s and CFO’s and its highly specialized skills and industry experience, including evaluating intellectual property.

Target Borrowers

  • Later stage bio-pharma and medical device development companies
  • Multi-product pipeline / platform / disruptive technologies
  • Strong institutional / strategic investor support
  • Broad and protected intellectual property position

Transaction Types

  • General refinancing
  • Growth capital

Typical Investment Size

$1M to $125M